Aziyo Biologics Overview
Latest ROE for Aziyo Biologics: 221.26% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow221.26%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, AZYO shows a ROE of 221.26%. That is above the Healthcare sector average of 29.33%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.33%. Aziyo Biologics is at 221.26%, which is higher that average. That is roughly 654.4% above the sector mean. Use the comparison chart on this page to see how AZYO stacks up against individual peers as well.
Check the historical chart to see whether AZYO's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Aziyo Biologics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Aziyo Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 221.26%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.33%, while AZYO is at 221.26%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
